Literature DB >> 26994323

Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia.

Joshua N Gustine1, Kirsten Meid1, Toni E Dubeau1, Steven P Treon1,2, Jorge J Castillo1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26994323     DOI： 10.1002/ajh.24366

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  11 in total

1.  What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy.

Authors:  Steven P Treon; Jorge J Castillo
Journal:  Blood Adv       Date:  2017-11-28

2.  Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.

Authors:  Tracy E Wiczer; Lauren B Levine; Jessica Brumbaugh; Jessica Coggins; Qiuhong Zhao; Amy S Ruppert; Kerry Rogers; Anli McCoy; Luay Mousa; Avirup Guha; Nyla A Heerema; Kami Maddocks; Beth Christian; Leslie A Andritsos; Samantha Jaglowski; Steven Devine; Robert Baiocchi; Jennifer Woyach; Jeffrey Jones; Michael Grever; Kristie A Blum; John C Byrd; Farrukh T Awan
Journal:  Blood Adv       Date:  2017-09-08

Review 3.  Management of Waldenström macroglobulinemia in 2020.

Authors:  Jorge J Castillo; Steven P Treon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

4.  A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.

Authors:  Constantine S Tam; Stephen Opat; Shirley D'Sa; Wojciech Jurczak; Hui-Peng Lee; Gavin Cull; Roger G Owen; Paula Marlton; Björn E Wahlin; Ramón Garcia Sanz; Helen McCarthy; Stephen Mulligan; Alessandra Tedeschi; Jorge J Castillo; Jaroslaw Czyz; Carlos Fernández de Larrea; David Belada; Edward Libby; Jeffrey V Matous; Marina Motta; Tanya Siddiqi; Monica Tani; Marek Trneny; Monique C Minnema; Christian Buske; Veronique Leblond; Judith Trotman; Wai Y Chan; Jingjing Schneider; Sunhee Ro; Aileen Cohen; Jane Huang; Meletios Dimopoulos
Journal:  Blood       Date:  2020-10-29       Impact factor: 22.113

Review 5.  What is new in the treatment of Waldenstrom macroglobulinemia?

Authors:  Jorge J Castillo; Steven P Treon
Journal:  Leukemia       Date:  2019-10-07       Impact factor: 11.528

Review 6.  New developments in the management of Waldenström macroglobulinemia.

Authors:  Jithma P Abeykoon; Uday Yanamandra; Prashant Kapoor
Journal:  Cancer Manag Res       Date:  2017-03-10       Impact factor: 3.989

7.  Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials.

Authors:  Jorge J Castillo; Joshua N Gustine; Kirsten Meid; Catherine A Flynn; Maria G Demos; Maria L Guerrera; Cristina Jimenez; Amanda Kofides; Xia Liu; Manit Munshi; Nicholas Tsakmaklis; Christopher J Patterson; Lian Xu; Guang Yang; Zachary R Hunter; Steven P Treon
Journal:  Hemasphere       Date:  2020-05-21

8.  Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia.

Authors:  Aristea-Maria Papanota; Ioannis Ntanasis-Stathopoulos; Efstathios Kastritis; Meletios A Dimopoulos; Maria Gavriatopoulou
Journal:  J Blood Med       Date:  2019-08-27

Review 9.  Waldenström macroglobulinemia treatment algorithm 2018.

Authors:  Morie A Gertz
Journal:  Blood Cancer J       Date:  2018-05-01       Impact factor: 11.037

10.  Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.

Authors:  Steven P Treon; Kirsten Meid; Joshua Gustine; Guang Yang; Lian Xu; Xia Liu; Christopher J Patterson; Zachary R Hunter; Andrew R Branagan; Jacob P Laubach; Irene M Ghobrial; M Lia Palomba; Ranjana Advani; Jorge J Castillo
Journal:  J Clin Oncol       Date:  2020-09-15       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.